Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite its efficacy, thalidomide's use has been limited by the agent's toxicity profile. In addition to the widely known teratogenic effects of ...

including linvoseltamab [BCMAxCD3 antibody], ubamatamab [MUC16xCD3 antibody], fianlimab [LAG-3 antibody], and more. After I discussed Regeneron's financial results for the fourth quarter of 2024 ...

Jim and Donna Vaccaro of the Village of De La Vista West were playing the Briarwood Executive Golf Course on Thursday, Feb. 13 when they both got holes-in-one on two different holes. Jim and Donna ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Lenalidomide, a thalidomide analogue, has produced good results when used with dexamethasone in patients with relapsed or refractory MM. Lenalidomide is associated with hematologic toxicities, and ...

Anna Baluch is a freelance writer from Cleveland, Ohio. She enjoys writing about a variety of health and personal finance topics. When she's away from her laptop, she can be found working out ...

Linvoseltamab's BLA resubmission is under FDA review, with a decision anticipated by July 2025, supported by LINKER-MM1 trial data. The trial evaluates linvoseltamab's safety, tolerability, and ...

Department of Materials Science and Engineering, University of California, Irvine, Irvine, California 92697, United States Department of Chemistry, Boston University, Boston, Massachusetts 02215, ...

TARRYTOWN, NY, USA I February 11, 2025 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the ...

Just as Andrew Witty of UnitedHealth Group did in a call with investors last month, CVS Health’s CEO David Joyner defended the role of PBMs in healthcare. CVS Health’s health services business, which ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Tuesday said that the resubmission of Biologics License Application (BLA) for linvoseltamab for the treatment of multiple myeloma has been ...

The BLA is supported by data from the pivotal LINKER-MM1 trial investigating linvoseltamab in R/R MM, and linvoseltamab is also under review by the European Medicines Agency (EMA) for the same ...